Skip to main content
. Author manuscript; available in PMC: 2021 Apr 14.
Published in final edited form as: Acta Haematol. 2020 Apr 14;143(6):567–573. doi: 10.1159/000506346

Table 2.

Venetoclax-based regimens in patients with Philadelphia chromosome-positive (Ph+) AML and CML myeloid blast phase (MBP)

Regimen Ph+ AML (n=7) CML MBP (n=9)
Decitabine-based 4 (57) 5 (56)
Intensive chemotherapy-based 3 (43) 4 (44)
BCR-ABL TKI
 Ponatinib 6 (86) 4 (44)
 Dasatinib 1 (14) 3 (33)
 Bosutinib 0 (0) 1 (11)
 Nilotinib 0 (0) 1 (11)
Results expressed as n (%)